Product Information
VARENICLINE 1 MG CONT MONTH BX is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.3503 per EA under NDC 68462089404. Its NADAC has been published 82 times since Jan 29, 2025.
FDA first approved this application on Aug 1, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the varenicline tartrate market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462089404
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
VARENICLINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA214255FDA Approved
8/1/2023
TE Code
AB
On Market Since
8/22/2023
Pharmacological Classes
Price Statistics
The NADAC for VARENICLINE 1 MG CONT MONTH BX has been published 82 times since Jan 29, 2025, and over the history we have for it it has declined 41.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3503 per EA |
|---|---|
| All-time high | $0.5970 (Feb 12, 2025) |
| All-time low | $0.3503 (Aug 19, 2026) |
| 52-week high | $0.5117 |
| 52-week low | $0.3503 |
| Median price | $0.4610 |
| Average price | $0.4790 |
| Largest weekly change | -8.7% (Aug 19, 2026) |
| Weeks tracked | 82 |
| Tracking since | Jan 29, 2025 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VARENICLINE 1 MG CONT MONTH BX?
The current National Average Drug Acquisition Cost (NADAC) for VARENICLINE 1 MG CONT MONTH BX, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.3503 per EA (NDC 68462089404), effective Aug 19, 2026.
How has the price of VARENICLINE 1 MG CONT MONTH BX changed over time?
Over the history we have for it, the NADAC for VARENICLINE 1 MG CONT MONTH BX has declined 41.3%. It has been tracked across 82 weekly CMS publications since Jan 29, 2025.
What are the highest and lowest recorded NADAC prices for VARENICLINE 1 MG CONT MONTH BX?
Since Jan 29, 2025, the NADAC for VARENICLINE 1 MG CONT MONTH BX has ranged from a low of $0.3503 (Aug 19, 2026) to a high of $0.5970 (Feb 12, 2025), with a median of $0.4610 per EA.
Are there cheaper alternatives to VARENICLINE 1 MG CONT MONTH BX?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as VARENICLINE 1 MG CONT MONTH BX in a comparable dosage form, but none are currently priced below it.
Who manufactures VARENICLINE 1 MG CONT MONTH BX?
VARENICLINE 1 MG CONT MONTH BX (NDC 68462089404) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.